Mild Cognitive Impairment

Country:

Washington, USA

Target group:

Patients with mild cognitive impairment

Use case:

Before dementia, early stages such as mild cognitive impairment (MCI) provide a crucial window for intervention but are challenging to detect. This study monitored 51 individuals over a year, using the SGMA Index on a weekly basis to track changes and identify early markers of cognitive decline.

 

MCI Clinical Diagnosis

MCI is commonly described as an intermediate stage between normal cognitive aging and dementia. In this study, MCI was defined as a decline in cognitive abilities exceeding what is typical for a person’s age and educational background (1–1.5 standard deviations below normative expectations) but not severe enough to meet the criteria for a dementia diagnosis (as recommended in Winblad et al., 2004). Diagnosis of MCI was based on a combination of clinical evaluation, cognitive testing, and medical history. Clinical evaluations were conducted by a geriatric psychiatrist or neurologist who assessed participants’ cognitive and functional abilities using standardized tools. Healthy controls were screened for cognitive impairment using the same methods as those applied to MCI participants.

Looking for support?

Connect with our dedicated research team—we’re ready to assist you!

Researcher at MemoryLab

Thomas
Wilschut

Researcher & Partnership Coordinator

Looking for support?

Connect with our dedicated research team—we’re ready to assist you!

Apply to use the SGMA

Fill out the form

Or send us a message

Thomas Wilschut

Researcher & Partnership Coordinator

Researcher at MemoryLab

Offerte aanvragen?

Vul het onderstaande formulier in:

Of mail naar:

Aan de slag!

Wilt u meer weten?

Vul het onderstaande formulier in:

Of mail naar: